Freedonia Market Research Analyzes Cardiac Implant Industry

Demand for cardiac implants in the US is projected to increase 8.8 percent annually to $16.4 billion in 2012.  Growth will rebound from a slowdown that intensified in 2007 when product recalls and safety controversies weakened the market for a number of devices.  The development of next generation models based on new technologies and improved materials will rectify recent performance problems experienced by implantable cardiac rhythm devices and lessen the thrombosis risk of drug-eluting coronary stents.  Shortcomings in existing drug therapies will promote the increasing use of cardiac implants in the treatment and management of coronary and peripheral heart diseases, cardiac arrhythmia, congestive heart failure and valvular heart defects. These and other trends are presented in Cardiac Implants, a new study from The Freedonia Group, Inc., a Cleveland-based industry market research firm.

Based on breadth of indications served, pacing devices will remain the top-selling group of cardiac implants, with demand expanding 7.8 percent annually to $8.7 billion in 2012.  Cardiac resynchronization therapy (CRT) devices will post the fastest growth among pacing devices as they greatly improve therapeutic outcomes in patients afflicted with congestive heart failure. 

The introduction of new drug-eluting stents with improved designs and a reduced risk of complications will boost the market for cardiac stents and stent-related implants over ten percent annually to $6.5 billion in 2012.  The new introductions will encourage the expansion of angioplasty as a treatment for coronary heart disease.  Other stents and stent-related implants projected to fare well in the marketplace include endovascular stent-grafts, femoral and related stents, and carotid stents. 

Demand for structural cardiac implants will remain comparatively low due to the limited indications served and smaller potential patient base.  Tissue heart valves and implantable heart monitors hold the best growth prospects among these products.  Tissue heart valves will capture demand away from mechanical heart valves in the treatment of valvular heart defects based on a reduced blood-clotting risk.  Advances in diagnostic capabilities will promote the increasing use of implantable heart monitors in patients with moderate-to-advanced congestive heart failure.      

The Freedonia Group is a leading international business research company, founded in 1985, that publishes more than 100 industry research studies annually. This industry analysis provides an unbiased outlook and a reliable assessment of an industry and includes product segmentation and demand forecasts, industry trends, demand history, threats and opportunities, competitive strategies, market share determinations and company profiles.